New drug KMY tablets enter first human safety tests
NCT ID NCT07314541
First seen Jan 06, 2026 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This early-phase trial will test the safety and tolerability of KMY tablets in 120 healthy adults aged 18 to 45. Participants will receive either the drug or a placebo, and researchers will monitor for side effects and how the drug moves through the body. The study also looks at how food affects drug absorption. Since this is a first-in-human trial, there is no direct treatment benefit for volunteers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Suzhou Municipal Hospital
Suzhou, Jiangsu, 215000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KMY Tablets
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.